

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Douglas Craig HOOPER, *et al.*

Application No.: 10/560,299
(International Application No. PCT/US2004/018613)

Filed: --
(International Filing Date: 10 June 2004 (10.06.2004))

For: **RECOMBINANT ANTIBODIES AND COMPOSITIONS AND
METHODS FOR MAKING AND USING THE SAME**

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying form PTO-1449, except for any U.S. patents and published U.S. patent applications which may be listed.

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10	
EXPRESS MAIL Mailing Label No:	<u>998813346 US</u>
Date of Deposit:	<u>April 12, 2006</u>
<p>I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>	
<u>Denise M. Collins</u> Signature of person mailing page:	
<u>Denise M. Collins</u> Type or print name of person	

This Information Disclosure Statement should not be construed as a representation that the cited references are material or prior art, or that more relevant references do not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

Douglas Craig HOOPER, et al.

BY 

DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 8321-221US	Int.'l. App. No.: PCT/US2004/018613
	APPLICANT: Douglas C. Hooper et al.	
	Int.'l. Filing Date: 10 June 2004	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	US 6,890,532	05/10/2005	Hooper et al.	424	147.1	
	AB	US 2003/0157112	08/21/2003	Hooper et al.	424	159.1	
	AC	US 2003/0165507	09/04/2003	Hooper et al.	424	147.1	
	AD	US 2004/0013672	01/22/2004	Hooper et al.	424	159.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	<u>TRANSLATION</u> YES NO	
	AE	WO 93/21319	10/28/1993	PCT	C12N	15/13	X	
	AF	EP 239,400	03/26/1987	Europe	C12N	15/00	X	
	AG	WO 89/09622	10/19/1989	PCT	A61K	39/395	X	
	AH	EP 338,745	03/01/1995	Europe	C12N	15/00	X	
	AI	EP 332,424	03/08/1989	Europe	C12N	15/00	X	
	AJ	WO 89/09789	10/19/1989	PCT	C07K	15/00	X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	B. Dietzschold, B., "Techniques For The Purification Of Rabies Virus, Its Subunits And Recombinant Products," <i>Laboratory Techniques in Rabies</i> , Meslin et al., (Eds.) World Health Organization, Geneva, pp. 175-80 (1996).
	AL	D. C. Hooper, "Rabies Virus", <i>Manual of Clinical Laboratory Immunology, Part II</i> , 5 th ed., N.R. Rose (Ed.), ASM Press, Wash. D.C., pp. 755-60 (1997).
	AM	W.R. Pearson, et al., "Improved Tools For Biological Sequence Comparison", <i>Proc. Natl. Acad. Sci. USA</i> , 1988 , <i>85</i> , 2444-48.
	AN	J. M. Champion, et al., "The Development Of Monoclonal Human Rabies Virus-Neutralizing Antibodies As A Substitute For Pooled Human Immune Globulin In The Prophylactic Treatment Of Rabies Virus Exposure", <i>J. Immunol. Methods</i> , 2000 , <i>235</i> , 81-90.
	AO	B. Dietzschold, et al., "Biological Characterization Of Human Monoclonal Antibodies To Rabies Virus", <i>J. Virol.</i> , 1990 , <i>64</i> , 3087-90.
	AP	S. C. Cheung, et al., "A Recombinant Human Fab Expressed in <i>Escherichia coli</i> Neutralizes Rabies Virus", <i>J. Virol.</i> , 1992 , <i>66</i> , No. 11, 6714-20.
	AQ	B. H. Muller, et al., "Phage-displayed and Soluble Mouse scFv Fragments Neutralize Rabies Virus", <i>J. Virol.</i> , 1997 , <i>67</i> , pages 221-33.
	AR	H. Ikematsu, et al., "Clonal Analysis of a Human Antibody Response", <i>J. Immunol.</i> , 1993 , <i>150</i> , pages 1325-37.
	AS	R. F. Rando et al., "Production of Human Monoclonal Antibodies Against Rabies Virus", <i>Curr. Top. Microbiol. Immunol.</i> , 1994 , <i>187</i> , 195-205.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 8321-221US	Int'l. App. No.: PCT/US2004/018613
	APPLICANT: Douglas C. Hooper et al.	
	Int'l. Filing Date: 10 June 2004	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT	J. Cruse et al., "Genetically Engineered Antibodies" in "Illustrated Dictionary of Immunology" p. 143 (CRC Press 1995).
AU	H. D. Foley <i>et al.</i> , "A Recombinant Rabies Virus Expressing Vesicular Stomatitis Virus Glycoprotein Fails to Protect Against Rabies Virus Infection", <i>Proc. Natl. Acad. Sci. USA</i> , 2000 , 97(26), 14680-85.
AV	T. Paterson <i>et al.</i> , "Variation in IgG1 Heavy Chain Allotype Does Not Contribute to Differences in Biological Activity of Two Human Anti-Rhesus (D) Monoclonal Antibodies", <i>Immunotechnology</i> , 1998 , 4(1), 37-47.
AW	M. Takekoshi et al., GenBank sequence ID 11275302 available at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=11275302 .
AX	A. Plückthun, "Antibody Engineering: Advances from the Use of <i>Escherichia Coli</i> Expression Systems", <i>Biotechnology</i> , 1991 , 9, 545-551.
AY	Report of the Sixth WHO Consultation on Monoclonal Antibodies In Rabies Diagnosis and Research, (WHO, 1990).
AZ	WHO Consultation on Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment, Geneva, (WHO, 2002).
BA	M. Schnell <i>et al.</i> , "Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1", <i>Proc. Natl. Acad. Sci. USA</i> , 2000 , 97(7), 3544-49.
BB	C. A. Hanlon, <i>et al.</i> , "Experimental Utility of Rabies Virus-Neutralizing Human Monoclonal Antibodies in Post-Exposure Prophylaxis, <i>Vaccine</i> , 2001 , 19, 3834-42.
BC	B. Dietzschold, <i>et al.</i> , "Development of a cocktail of human recombinant anti-rabies virus monoclonal antibodies for post-exposure treatment of human rabies", XIII International Meeting On Research Advanced and Rabies Control in the Americas, November 3-8, 2002, Oaxaca City, Mexico (abstract; due to poor legibility of the copy a transcript of the abstract is also included).
BD	C.L. Schumacher, <i>et al.</i> , "Inhibition of Immune Responses Against Rabies Virus by Monoclonal Antibodies Directed Against Rabies Virus Antigens", <i>Vaccine</i> , 1992 , 01, 754-60.
BE	"Rabies Vaccines. WHO Position Paper", <i>Weekly Epidemiological Record</i> , 2002 , 77, 109-20 (WHO, 2002).
BF	B. Dietzschold, <i>et al.</i> , "New Approaches to the Prevention and Eradication of Rabies", <i>Expert Rev. Vaccines</i> , 2003 , 2(3), 89-96.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
8321-221US

Int.'l. App. No.:

PCT/US2004/018613

APPLICANT:

Douglas C. Hooper et al.

Int.'l. Filing Date:

10 June 2004

GROUP

Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	US 6,890,532	05/10/2005	Hooper et al.			
	AB	US 2003/0157112	08/21/2003	Hooper et al.	424	147.1	
	AC	US 2003/0165507	09/04/2003	Hooper et al.	424	159.1	
	AD	US 2004/0013672	01/22/2004	Hooper et al.	424	147.1	
				Hooper et al.	424	159.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AE	WO 93/21319	10/28/1993	PCT				
	AF	EP 239,400	03/26/1987	Europe	C12N	15/13	X	
	AG	WO 89/09622	10/19/1989	PCT	C12N	15/00	X	
	AH	EP 338,745	03/01/1995	Europe	A61K	39/395	X	
	AI	EP 332,424	03/08/1989	Europe	C12N	15/00	X	
	AJ	WO 89/09789	10/19/1989	Europe	C12N	15/00	X	
				PCT	C07K	15/00	X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AK	B. Dietzschold, B., "Techniques For The Purification Of Rabies Virus, Its Subunits And Recombinant Products," <i>Laboratory Techniques in Rabies</i> , Meslin et al., (Eds.) World Health Organization, Geneva, pp. 175-80 (1996).
AL	D. C. Hooper, "Rabies Virus", <i>Manual of Clinical Laboratory Immunology, Part II</i> , 5 th ed., N.R. Rose (Ed.), ASM Press, Wash. D.C., pp. 755-60 (1997).
AM	W.R. Pearson, et al., "Improved Tools For Biological Sequence Comparison", <i>Proc. Natl. Acad. Sci. USA</i> , 1988, 85, 2444-48.
AN	J. M. Champion, et al., "The Development Of Monoclonal Human Rabies Virus-Neutralizing Antibodies As A Substitute For Pooled Human Immune Globulin In The Prophylactic Treatment Of Rabies Virus Exposure", <i>J. Immunol. Methods</i> , 2000, 235, 81-90.
AO	B. Dietzschold, et al., "Biological Characterization Of Human Monoclonal Antibodies To Rabies Virus", <i>J. Virol.</i> , 1990, 64, 3087-90.
AP	S. C. Cheung, et al., "A Recombinant Human Fab Expressed in <i>Escherichia coli</i> Neutralizes Rabies Virus", <i>J. Virol.</i> , 1992, 66, No. 11, 6714-20.
AQ	B. H. Muller, et al., "Phage-displayed and Soluble Mouse scFv Fragments Neutralize Rabies Virus", <i>J. Virol.</i> , 1997, 67, pages 221-33.
AR	H. Ikematsu, et al., "Clonal Analysis of a Human Antibody Response", <i>J. Immunol.</i> , 1993, 150, pages 1325-37.
AS	R. F. Rando et al., "Production of Human Monoclonal Antibodies Against Rabies Virus", <i>Curr. Top. Microbiol. Immunol.</i> , 1994, 187, 195-205.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 8321-221US	Int.'l. App. No.: PCT/US2004/018613
	APPLICANT: Douglas C. Hooper et al.	
	Int.'l. Filing Date: 10 June 2004	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	<u>TRANSLATION</u> YES NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AT	J. Cruse et al., "Genetically Engineered Antibodies" in "Illustrated Dictionary of Immunology" p. 143 (CRC Press 1995).
AU	H. D. Foley <i>et al.</i> , "A Recombinant Rabies Virus Expressing Vesicular Stomatitis Virus Glycoprotein Fails to Protect Against Rabies Virus Infection", <i>Proc. Natl. Acad. Sci. USA</i> , 2000 , 97(26), 14680-85.
AV	T. Paterson <i>et al.</i> , "Variation in IgG1 Heavy Chain Allotype Does Not Contribute to Differences in Biological Activity of Two Human Anti-Rhesus (D) Monoclonal Antibodies", <i>Immunotechnology</i> , 1998 , 4(1), 37-47.
AW	M. Takekoshi et al., GenBank sequence ID 11275302 available at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=11275302 .
AX	A. Plückthun, "Antibody Engineering: Advances from the Use of <i>Escherichia Coli</i> Expression Systems", <i>Biotechnology</i> , 1991 , 9, 545-551.
AY	Report of the Sixth WHO Consultation on Monoclonal Antibodies In Rabies Diagnosis and Research, (WHO, 1990).
AZ	WHO Consultation on Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment, Geneva, (WHO, 2002).
BA	M. Schnell <i>et al.</i> , "Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1", <i>Proc. Natl. Acad. Sci. USA</i> , 2000 , 97(7), 3544-49.
BB	C. A. Hanlon, <i>et al.</i> , "Experimental Utility of Rabies Virus-Neutralizing Human Monoclonal Antibodies in Post-Exposure Prophylaxis, <i>Vaccine</i> , 2001 , 19, 3834-42.
BC	B. Dietzschold, <i>et al.</i> , "Development of a cocktail of human recombinant anti-rabies virus monoclonal antibodies for post-exposure treatment of human rabies", XIII International Meeting On Research Advanced and Rabies Control in the Americas, November 3-8, 2002, Oaxaca City, Mexico (abstract; due to poor legibility of the copy a transcript of the abstract is also included).
BD	C.L. Schumacher, <i>et al.</i> , "Inhibition of Immune Responses Against Rabies Virus by Monoclonal Antibodies Directed Against Rabies Virus Antigens", <i>Vaccine</i> , 1992 , 01, 754-60.
BE	"Rabies Vaccines. WHO Position Paper", <i>Weekly Epidemiological Record</i> , 2002 , 77, 109-20 (WHO, 2002).
BF	B. Dietschold, <i>et al.</i> , "New Approaches to the Prevention and Eradication of Rabies", <i>Expert Rev. Vaccines</i> , 2003 , 2(3), 89-96.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.